STOCK TITAN

DexCom Executive's Latest Stock Sale Follows $526K Trading Pattern in Q2

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

DexCom (NASDAQ: DXCM) Officer Sadie Stern has filed a Form 144 notice indicating a proposed sale of 1,466 shares of common stock with an aggregate market value of $124,697.96. The planned transaction is scheduled for execution on June 26, 2025, through Morgan Stanley Smith Barney LLC.

The shares to be sold were acquired as Restricted Stock from the issuer on November 19, 2023. The filing also discloses Stern's recent trading activity, showing three previous sales in May 2025 totaling 6,184 shares with combined gross proceeds of $526,318.38.

The transaction is being executed under a Rule 10b5-1 trading plan adopted on February 20, 2025. As of the filing date, DexCom has 392,107,501 shares outstanding. The seller has certified no knowledge of material adverse non-public information regarding the company's operations.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many DXCM shares is Sadie Stern planning to sell according to the Form 144 filing from June 28, 2025?

According to the Form 144 filing, Sadie Stern, an officer at DexCom, plans to sell 1,466 shares of DXCM common stock with an aggregate market value of $124,697.96 through Morgan Stanley Smith Barney LLC.

What was the total value of DXCM shares sold by Sadie Stern in the past 3 months before this Form 144 filing?

In the three months prior to this filing, Sadie Stern sold a total of 6,184 DXCM shares in three separate transactions on May 27, 2025, generating total gross proceeds of $526,318.38.

When did Sadie Stern acquire the DXCM shares mentioned in this Form 144?

The shares were acquired on November 19, 2023, as restricted stock directly from the issuer (DexCom). The filing indicates 1,466 shares were acquired on this date.

Does DXCM executive Sadie Stern's Form 144 filing indicate a 10b5-1 trading plan?

Yes, the filing indicates that Stern is relying on a Rule 10b5-1 trading plan that was adopted on February 20, 2025. This suggests the planned sale is part of a predetermined trading schedule.

What is the current number of outstanding DXCM shares according to the June 2025 Form 144?

According to the Form 144 filing, DexCom (DXCM) has 392,107,501 shares outstanding as of the filing date.
Dexcom Inc

NASDAQ:DXCM

DXCM Rankings

DXCM Latest News

DXCM Latest SEC Filings

DXCM Stock Data

27.12B
388.32M
0.42%
97.51%
2.83%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO